367 related articles for article (PubMed ID: 16389295)
21. Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses.
Cumberbatch MJ; Hill RG; Hargreaves RJ
Cephalalgia; 1998 Dec; 18(10):659-63. PubMed ID: 9950621
[TBL] [Abstract][Full Text] [Related]
22. Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan.
Gueorguieva I; Nestorov IA; Aarons L; Rowland M
Pharm Res; 2005 Oct; 22(10):1614-26. PubMed ID: 16180118
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on eletriptan in migraine.
McCormack PL; Keating GM
CNS Drugs; 2006; 20(11):961-4. PubMed ID: 17044732
[TBL] [Abstract][Full Text] [Related]
24. Ischemic colitis associated with naratriptan and oral contraceptive use: a response.
Malone TD; Kori SH
Headache; 2005; 45(10):1418-9; author reply 1419-20. PubMed ID: 16324179
[No Abstract] [Full Text] [Related]
25. [Zolmitriptan].
Monseu G; Sternon J
Rev Med Brux; 1998 Dec; 19(6):495-9. PubMed ID: 9916496
[TBL] [Abstract][Full Text] [Related]
26. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
Mathew NT; Asgharnejad M; Peykamian M; Laurenza A
Neurology; 1997 Dec; 49(6):1485-90. PubMed ID: 9409334
[TBL] [Abstract][Full Text] [Related]
27. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack PL; Foster RH
Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
[TBL] [Abstract][Full Text] [Related]
28. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists.
Levy D; Jakubowski M; Burstein R
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4274-9. PubMed ID: 15016917
[TBL] [Abstract][Full Text] [Related]
29. Spotlight on rizatriptan in migraine.
Wellington K; Jarvis B
CNS Drugs; 2002; 16(10):715-20. PubMed ID: 12269863
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic evaluation of frovatriptan.
Negro A; Lionetto L; Casolla B; Lala N; Simmaco M; Martelletti P
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1449-58. PubMed ID: 21929465
[TBL] [Abstract][Full Text] [Related]
31. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Ashcroft DM; Millson D
Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):73-82. PubMed ID: 14998068
[TBL] [Abstract][Full Text] [Related]
32. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group.
Heywood J; Bomhof MA; Pradalier A; Thaventhiran L; Winter P; Hassani H
Cephalalgia; 2000 Jun; 20(5):470-4. PubMed ID: 11037743
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Deleu D; Hanssens Y
J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409
[TBL] [Abstract][Full Text] [Related]
34. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.
Sheftell F; O'Quinn S; Watson C; Pait D; Winter P
Headache; 2000 Feb; 40(2):103-10. PubMed ID: 10759909
[TBL] [Abstract][Full Text] [Related]
35. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
Klassen A; Elkind A; Asgharnejad M; Webster C; Laurenza A
Headache; 1997; 37(10):640-5. PubMed ID: 9439085
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
Garcia-Ramos G; MacGregor EA; Hilliard B; Bordini CA; Leston J; Hettiarachchi J
Cephalalgia; 2003 Nov; 23(9):869-76. PubMed ID: 14616928
[TBL] [Abstract][Full Text] [Related]
37. Building on the sumatriptan experience: the development of naratriptan.
Connor HE
Cephalalgia; 2001; 21 Suppl 1():32-4. PubMed ID: 11678820
[No Abstract] [Full Text] [Related]
38. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Deleu D; Hanssens Y
Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
[TBL] [Abstract][Full Text] [Related]
39. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
40. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate.
Lambert GA; Boers PM; Hoskin KL; Donaldson C; Zagami AS
Brain Res; 2002 Oct; 953(1-2):181-8. PubMed ID: 12384251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
